NCT05806814 - Sipuleucel-T Based Autologous Cellular Immunotherapy for Advanced Prostate Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 12, 2023

Primary Completion Date

June 30, 2026

Study Completion Date

December 31, 2026

Conditions

Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Interventions

BIOLOGICAL

Sipuleucel-T

Three doses of Sipuleucel-T, each containing a minimum of 50 million autologous CD54+ cells activated with PAP-GM-CSF, given at week 0, 2, and 12-14.

Trial Locations (1)

RECRUITING

University of Oklahoma Health Sciences Center, Stephenson Cancer Center, Oklahoma City